10.67  0 (0%)		01-29 16:00
Open: 10.67 High: 10.67 Volume: 84,893		Pre. Close: 10.67 Low: 10.67 Market Cap: 337(M)

Short term
Mid term
Targets	6-month :	12.46	1-year :	14.55
Resists	First :	10.67	Second :	12.46
Pivot price	10.64
Supports	First :	10.6	Second :	10.56
MAs	MA(5) :	10.66	MA(20) :	10.64
	MA(100) :	10.53	MA(250) :	10.38
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	100	D(3) :	98.6
RSI	RSI(14): 70.4
52-week	High :	10.98	Low :	10.06

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VACH ] has closed below upper band by 2.5%. Bollinger Bands are 26.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.69 - 10.74	10.74 - 10.78
Low:	10.54 - 10.6	10.6 - 10.65
Close:	10.59 - 10.68	10.68 - 10.75

Voyager Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company has not selected any specific business combination target and has not initiated any substantive discussions with potential targets.

Thu, 08 Jan 2026
Voyager Acquisition (NASDAQ:VACH) Shares Down 0.2% - Here's Why - MarketBeat

Tue, 20 May 2025
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer - BioSpace

Fri, 25 Apr 2025
Duane Morris Represents Veraxa in $1.3 Billion SPAC Merger Agreement - Duane Morris LLP

Wed, 23 Apr 2025
Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal - Reuters

Tue, 22 Apr 2025
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies - TradingView

Fri, 30 Jan 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	25 (M)
Shares Float	18 (M)
Held by Insiders	28.6 (%)
Held by Institutions	101.1 (%)
Shares Short	26 (K)
Shares Short P.Month	1 (K)

EPS	0.3
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.39
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	11.1 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	35.56
PEG Ratio	0
Price to Book value	-27.36
Price to Sales	0
Price to Cash Flow	-533.99

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.